Treatment of renal cancer patients with gemcitabine (2′,2′-difluorodeoxycytidine) and interferons: Antitumor activity and toxicity

Oncology Reports

Volumn 5, Issue 6, 1998, Pages 1555-1560

  Rohde, Detlef ^a   Thiemann, Dirk ^a   Wildberger, Joachim ^a   Wolff, Johannes ^b   Jakse, Gerhard ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b NONE

Author keywords

2 ,2 difluorodeoxycytidine; Interferon; Metastases; Pilot study; Renal cell carinoma

Indexed keywords

GEMCITABINE; RECOMBINANT GAMMA INTERFERON;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CYTOSTASIS; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; INTERFERON ALFA-2A; INTERFERON-GAMMA, RECOMBINANT; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING;

EID: 0031715098     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.6.1555     Document Type: Article

References (27)

1. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC and Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4422, 1990.
2. Bouffard DY, Momparler LF and Momparler RL: Comparison of antineoplastic activity of 2′,2′-difluoro-deoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. Anticancer Drugs 2: 49-55, 1991.
3. Ruiz-van-Haperen VW, Veerman G, Vermorken JB and Peters GJ: 2′,2′-difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 46: 762-766, 1993.
4. Ruiz-van-Haperen VW, Veermann G, Boven E, Nordhuis P, Vermorken JB and Peters GJ: Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem Parmacol 48: 1327-1339, 1994.
5. Shewach DS, Hahn TM, Chang E, Hertel LW and Lawrence TS: Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54: 3218-3223, 1994.
6. Rohde D, De Mulder PHM, Weissbach L, Osieka R, Blatter J and Jakse G: Experimental and clinical efficacy of 2′,2′-difluorodeoxycytidinc (gemcitabine) against renal cell carcinoma. Oncology 53: 476-481, 1996.
7. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38: 567-572, 1990.
8. Gandhi V, Huang P and Xu YZ: Metabolism and action of 2′,2′-dsfluorodeoxycytidine: self potentiation of cytotoxicity. In: Purine and Pyrimidine Metabolism in Man. Vol. VII. Harkness RD (ed.) Plenum Press, New York, pp 125-130, 1991.
9. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA-synthesis. Cancer Res 51: 6110-6117, 1991.
10. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W: Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 52: 533-539, 1992.
11. Xu XZ and Plunkett W: Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2′,2′-difluorodeoxycytidine. Biochem Pharmacol 44: 1819-1827, 1992.
12. Abratt RP, Bezwoda W, Falkson G, Goedhals L, Hacking D and Rugg TA: Efficacy and safety profile of gemcitabine in nonsmall cell lung cancer: a phase II study. J Clin Oncol 12: 1535-1540, 1994.
13. Anderson H, Lund B, Bach F, Thatcher N, Walling J and Hansen HH: Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 12: 1821-1826, 1994.
14. Gatzemeier U, Shepherd F, Le Chevalier T, Weynants P, Cottier B, Groen HJ, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Burkes RL, Gottfried M and Voi M: Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32A: 243-248, 1996.
15. Lund B, Hansen OP, Theiladek, Hansen M and Neijt JP: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530-1533, 1994.
16. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J and Harris AL: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13: 2713-2736, 1995.
17. Catimel G, Vermorken JB, Clavel M, De Mulder P, Judson I, Sessa L, Piccart M, Bruntsch U, Verweij J, Wanders J, Franklin H and Kaye SB: A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 543-547, 1994.
18. Casper ES, Green MR, Kelson DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B and Tarassoff PG: Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29-34, 1994.
19. Mertens WC, Eisenhauer EA, Moore M, Venner P, Stewart D, Muldal A and Wong D: Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 4: 331-332, 1993.
20. De Mulder PHM, Weissbach L, Jakse G, Osieka R and Blatter J: Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 37: 491-495, 1996.
21. Rohde D, Hayn HK, Blatter J and Jakse G: The efficacy of 2′,2′-difluorodeoxycytidine (gemcitabine) combined with Interferon in human renal cell carcinoma cell lines. Int J Oncol 12: 1361-1366, 1998.
22. Rohde D, Goertz M, Blatter J and Jakse G: The efficacy of 2′,2′-difluorodeoxycytidine (gemcitabine) and vinblastine combined with Interferon in nude mice xenografts of human renal cell carcinoma. Int J Oncol 12: 1367-1372, 1998.
23. Atzpodien J, Kirchner H, Haenninen EL, Deckert M, Fenner M and Poliwoda H: Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell carcinoma. Eur J Cancer 29A (Suppl 5): 6-8, 1993.
24. Creagan ET, Buckner JC, Hahn RG, Richardson RR, Schaid DJ and Kovach JS: Evaluation of recombinant leukocyte A interferon with aspinn in patients with metastatic renal cell cancer. Cancer 61: 1787-1791, 1988.
25. Motzer RJ, Schwartz L, Murray Law T, Murphy BA, Hoffman AD, Albino AP, Vlamis V and Nanus DM: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13: 1950-1957, 1995.
26. The WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva, pp48, 1979.
27. Poplin EA, Carbett T, Flaherty L, Tarassoff P, Redman BG, Valdivieso M and Baker L: Difluorodeoxycytidine (dFdC) -aemcitabine: a phase I study. Invest New Druas 10: 165-170, 1992